Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for treatment-resistant depression
ACTRN12623001004651Phase 2Recruiting
- Sponsor
- Australian National University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin and adenosine-5′-monophosphate in treatment-resistant depression (TRD) and major depressive disorder (MDD) (4 arms), sponsored by Australian National University. Primary endpoint: Hamilton Depression Scale (HAM-D) continuous score. Started Sep 2024; status: recruiting.
02
Drugs
psilocybinadenosine-5′-monophosphate
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12623001004651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001004651.